10q10k10q10k.net
LivaNova PLC

LivaNova PLCLIVNEarnings & Financial Report

Nasdaq

LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

NextFeb 27, 2026

LIVN Q3 2025 Key Financial Metrics

Revenue

$357.8M

Gross Profit

$244.9M

Operating Profit

$54.0M

Net Profit

$26.8M

Gross Margin

68.4%

Operating Margin

15.1%

Net Margin

7.5%

YoY Growth

12.5%

EPS

$0.49

Financial Flow

LivaNova PLC Q3 2025 Financial Summary

LivaNova PLC reported revenue of $357.8M for Q3 2025, with a net profit of $26.8M (7.5% margin). Cost of goods sold was $112.9M, operating expenses totaled $190.8M.

Key Financial Metrics

Total Revenue$357.8M
Net Profit$26.8M
Gross Margin68.4%
Operating Margin15.1%
Report PeriodQ3 2025

LivaNova PLC Annual Revenue by Year

LivaNova PLC annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.3B).

YearAnnual Revenue
2024$1.3B
2023$1.2B
2022$1.0B

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$310.1M$294.9M$318.6M$318.1M$321.8M$316.9M$352.5M$357.8M
YoY Growth12.8%12.0%8.4%11.2%3.8%7.4%10.7%12.5%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$2.43B$2.46B$2.45B$2.52B$2.51B$2.56B$2.51B$2.56B
Liabilities$1.15B$1.24B$1.21B$1.21B$1.19B$1.52B$1.38B$1.40B
Equity$1.28B$1.22B$1.24B$1.31B$1.32B$1.03B$1.12B$1.16B

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$54.0M$10.0M$43.4M$51.0M$78.7M$24.0M$62.9M$85.1M